logo
8 ways to manage your child's weight as first 1,000 days of life found to be critical

8 ways to manage your child's weight as first 1,000 days of life found to be critical

Yahooa day ago
Experts have warned that child obesity has risen to "alarming" levels and are calling for action to prevent unhealthy lifestyles setting in among babies and toddlers.
The first 1,000 days of a child's life – from pregnancy through to their second birthday – are paramount when it comes to their health trajectory, the experts stated, and this period is "critical to development and health across the life-course."
From their observations, academics at the UK Academy of Medical Sciences and the Italian National Academy of Sciences also noted how difficult it was to change that trajectory once a child reaches five years of age.
"The overall goal should be to establish and maintain a healthy body-weight trajectory that avoids excess gain early in life," they said.
It comes after another study earlier this year, which also warned that being overweight as a child could double the risk of being obese as an adult.
The research, which tracked the body mass index (BMI) of thousands of children in the Netherlands, not only found that the first five years of a child's life are vital in preventing excess weight gain in the future, but also that the BMI of six-year-olds was the most reliable indicator of obesity later on in life.
More than a quarter of children (26.8%) aged two to 15 are overweight or obese in England, according to government figures. Experts have suggested the number of obese children and adults in the UK will rise substantially by 2050, with kids aged five to 14 bearing the brunt.
Girls in this age group will see a 53% rise in obesity levels, per the global analysis, and boys a 57% rise.
So, what can parents do at home to help reduce the risk of obesity in their children?
Mindful eating techniques, such as eating more slowly, have been proven to help children and adults digest their food properly.
They also improve nutrients absorption and promote healthier relationships with food, encouraging a better appreciation of food, and helping people establish when they are full.
Other mindful eating techniques for children include:
Limiting distractions while they eat
Asking for hunger cues before, during and after they eat
Engaging all fives senses when they eat
Discussing how different foods impact their mood, feelings and productivity
Studies have shown that snacking is more prevalent among those who are obese, but grazing can have other implications. Of course it depends on what your child is eating and how often they are picking, but snacking also affects their appetite and often includes ultra-processed foods, which can be harmful in other ways.
Alarmingly, a recent study by UCL published in the European Journal of Nutrition found that nearly half (47%) of the calories obtained by toddlers in the UK are from UPFs and 59% of calories obtained by those aged seven are derived from UPFs.
Portion size is also key. Children should not be eating adult-sized meals. So, as well as reducing the amount of food you are giving them, assess the crockery you are using – smaller plates will help you establish child-appropriate servings.
Your little one may have an aversion to broccoli or Brussels sprouts, but there are smarter ways to incorporate veggies into their diets that don't involve mealtime meltdowns.
For example, nutritionist Emily English (known as Em the Nutritionist online) has a viral five-a-day lasagne that involves mincing mushrooms, celery and other vegetables into a pulse, to add to the meat (optional). You cannot taste the individual vegetables disguised in the dish, but they add goodness and mean your whole family is benefiting from a healthier meal.
Just as we cannot expect our kids to put their phones and tablets down if we're forever glued to our screens, we cannot expect them to eat healthily and adopt positive lifestyle changes if we're not leading by example.
So, as well as ensuring the entire family is sticking to a healthy, balanced diet, be mindful of how you discuss food and exercise around them.
Speaking of exercise, a great way to get your kids going is to adopt more active approaches as a family. Whether it's weekend walks, daily runs to the park with the dog or team sports – adding regular exercise to their week can really go a long way.
Setting strict bedtimes and establishing a nighttime routine is beneficial. Not only does good quality sleep help bolster their mood and productivity, it can impact their weight and overall health.
Discuss with your child realistic targets for them – and your whole family – to achieve, and ensure you reward positive behaviour and give encouraging feedback as they go.
With both diet and exercise, the main thing is consistency – in terms of what you eat and do, how often you do it, and when you do it.
Sticking to the same mealtimes, having designated exercise slots and creating consistent portions and meal types will help establish healthy habits – both in the short- and long-term.
Read more about children's health and parenting
Seven signs your child could be struggling with their mental health (Yahoo Life UK)
How to spot anxiety in your child and how to help them (Yahoo Life UK, 6-min read)
Six things parents should know about Sabrina Carpenter's Short N' Sweet tour (Yahoo Life UK, 7-min read)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Evolving Approaches in Melanoma Treatment
Evolving Approaches in Melanoma Treatment

Medscape

timean hour ago

  • Medscape

Evolving Approaches in Melanoma Treatment

This transcript has been edited for clarity. Hello, everybody. I am Teresa Amaral, head of the Skin Cancer Clinical Trials Center at Tübingen University Hospital in Germany. I'm here directly from ASCO 2025 to discuss with you a couple of works that have been presented here and I think are important for you to know about and discuss. We are already in June, but last month was Melanoma and Skin Cancer Awareness Month. I think it's interesting that one of the posters and one of the works that was selected to be discussed here was associated with strategies and interventions to prevent melanoma and other skin cancers — namely, works and interventions that have been done in kids and young adults in order to prevent ultraviolet exposure. This is something that you don't see often. It's talked about frequently, but these kinds of interventions are not very common. It's very interesting to see that this has been selected to be discussed here. Well, that was part of the prevention, and now we go to early-stage melanoma. As you can imagine, and as you probably know, the majority of the patients that are diagnosed with melanoma are actually diagnosed at an early stage. This means stage I and stage II. Being the majority of the population that is diagnosed with melanoma, it's also the population for which we don't have any approved therapy, especially until stage IIA. What can we do for these patients? There have been a couple of works presented here at ASCO using artificial intelligence to look at slides from patients and from primary tumors of patients diagnosed with early-stage melanoma. Actually, these have been pretty promising for predicting the risk for recurrence of these early-stage patients. In this transcript to accompany the video, we've linked the posters and you can get more information if you want to look into more detail at the data that have been presented. Another work that I would like to call your attention to, for which I definitely have some bias because it's the poster that I presented here, is a gene expression profile also using the primary tumor of patients diagnosed with early-stage melanoma — so stage I and stage II. The majority of the patients had stage IA disease. We looked into the primary tumors and tried to identify the patients that are at higher risk of developing a recurrence without having the information of the sentinel lymph node biopsy. Looking into those who have high risk is one of the ways to look into this population, but also looking into those who have low risk and can safely forgo other evaluations or other interventions such as further follow-up, skin checks, ultrasounds, blood tests, and so on. Then moving into the adjuvant setting, where we already have some therapy that is reimbursed. For stage II, we have immunotherapy. For stage III, we have immunotherapy and targeted therapy for the patients with BRAF mutation. Some of the data that has been presented here are looking into different ways of not only clinical data, but also gene expression profile, next-generation sequencing, and other assays such as circulating tumor DNA, and combining all this information to try to understand who are the patients that will have a recurrence, and if we can see it from the very beginning in those patients who received adjuvant therapy. There were a couple of posters looking into this, showing that in principle, and based on these data, we might not have only one biomarker that can tell us which patients are those who, despite therapy, will recur, or which patients who, under therapy, will have a benefit. Interestingly enough, we also have other trials being presented on Tuesday, and we'll have another session looking into detail at trial data on targeted therapy in the adjuvant setting — the COLUMBUS-AD study— and also a negative trial, the Bristol Myers Squibb trial RELATIVITY-098, which looked into programmed cell death protein 1 (PD-1) vs PD-1 plus lymphocyte activation gene 3 in patients in stage III. I think this is a very important trial, and it's important that these negative trials are also presented and are discussed so that we can understand which patients really don't benefit and what we can use from these trials to move the investigation forward. Another interesting poster that was presented here is looking into patients receiving adjuvant therapy with immunotherapy or targeted therapy if they have a BRAF mutation. Why is this poster interesting? I would say that there are some conflicting data on what type of therapy you should use in the adjuvant setting if the patients have a BRAF mutation. There are some retrospective data showing that targeted therapy upfront might be better. The poster presented here shows that immunotherapy actually seems to do better, although the majority of the patients were indeed treated with immunotherapy, not targeted therapy. I think real-world data and retrospective data are more important every day because I don't expect to have any trial in the future looking into adjuvant targeted therapy or immunotherapy for patients with stage III melanoma. Besides the BRAF mutation, we will definitely need other biomarkers that will help to guide our decisions for patients who have BRAF -mutated stage III melanoma. Moving into the advanced setting, the most important questions that we want to get answered are not what we should use in first-line therapy because this is, I would say, pretty clear for the majority of patients. We have data from the SECOMBIT trial. We have data from the DREAMseq trial saying that patients will probably benefit more from immunotherapy upfront, even when they have a BRAF mutation. Very particular patients will be candidates for having targeted therapy upfront, as the majority of them will receive immunotherapy. This is exactly what is going to be presented on Tuesday from the DREAMseq study. The data will show that after 5 years, there is almost twice as high overall survival rate in patients that started with immunotherapy and three times better progression-free survival for patients that started with immunotherapy as compared to targeted therapy alone. There are some nuances from this trial because not all the patients that started with immunotherapy or targeted therapy did the crossover; many had brain metastases, which was one of the exclusion criteria for the crossover. Still, it shows that for the majority of the patients, you should start, if possible, with immunotherapy in the first line. It will be interesting to understand what to do for patients for whom we don't have a benefit using PD-1 therapy. There come the second-line therapies and more, I would say, experimental data on other strategies that include cell therapy and tumor-infiltrating lymphocyte (TIL) therapy. There have been some data presented in a poster, showing that patients who received TIL therapy have a good long-term outcome 5 years after this therapy. This might be a therapy that could possibly be given to a specific subgroup of patients in a very selected population. Also interesting would be to look into the same strategy without using the lympho depletion that is normally associated with this type of therapy and the interleukin-2 that is also given because this is, first, one of the limitations to select the patients that will get this therapy, and second, these two therapies are responsible for the majority of the toxicity that we see with this therapy. These are really interesting data to see how we can bring this therapy to our patients, but also how we can do it with reducing toxicity. Finally, one of our other treatments that has been discussed here and will also probably come in our future discussions are treatment-directed therapies — so local therapies such as injection therapies and viral therapies. These have been coming on the scene again, with new data from a different type of viral therapy but also with a combination of PD-1 therapy, which I think is quite interesting because they are looking into patients that really didn't benefit from PD-1 therapy. For the future, these would be my two or three populations where I think we need more data and we should definitely invest more in future trials. First, for early-stage trials, and again, looking into trials that are biomarker-selected. I don't think we can go on doing adjuvant trials in all the populations of patients with stage II and stage III. Second, for patients who did not benefit from PD-1 therapy in the advanced setting, but also those who received PD-1 in the adjuvant setting and did not benefit from that. And third, for patients with brain metastasis, which is obviously a difficult-to-treat population for which we don't have many options. Finally, there were some posters also analyzing treatment for patients with acral melanoma and mucosal melanoma, which again are populations that normally are excluded. It's nice to see that some companies are still investing in that. Also, there are some retrospective data showing that, despite the fact that patients do not benefit as much as those with normal cutaneous melanoma, there is still plenty of space to investigate new treatment avenues for this population that normally is excluded from clinical trials. This was my summary from what we know so far from ASCO 2025. I'll get back to you with a second take on this interesting meeting when we have the late-breaking abstracts presented in the rapid oral communications, and also in the oral communications, which I think might also come in handy when you want to decide what to do with your patients in the clinics next week. I hope you enjoyed the meeting, and I'm looking forward to seeing you again soon. Thank you.

GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat

Associated Press

timean hour ago

  • Associated Press

GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat

With COVID-19 continuing to mutate and over 40 million immunocompromised Americans still at risk, GeoVax's GEO-CM04S1 vaccine offers potential broader, more durable protection through a unique multi-antigen approach ATLANTA, GA - July 3, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today emphasized the urgent need for innovation in COVID-19 vaccination as the NB.1.8.1 variant - commonly known as 'Nimbus' - spreads rapidly across the globe. Nimbus, a highly transmissible Omicron subvariant classified by the World Health Organization as a 'Variant Under Monitoring,' is now dominant in multiple U.S. states and surging across Europe and Asia. Though not more severe, its rapid spread and potential for immune escape reflect an increasingly clear reality: COVID-19 is not going away, and it will continue to evolve. 'The emergence of the Nimbus variant is a stark reminder that we need 'smarter' vaccines, not just newer ones,' said David Dodd, Chairman and CEO of GeoVax. 'Our GEO-CM04S1 vaccine was designed for this purpose and is built to potentially provide broader and longer-lasting protection, especially for the immunocompromised patients most at risk.' GEO-CM04S1: Multi-Antigen Protection for the Immunocompromised Unlike mRNA vaccines that rely solely on the Spike protein, GEO-CM04S1 delivers both Spike (S) and Nucleocapsid (N) antigens, stimulating an immune response that includes not only an antibody response, but also robust T-cell activity. This is believed to be critical for cross-variant protection and extended durability, particularly in individuals with weakened immune systems. GEO-CM04S1 is currently being evaluated in two Phase 2 clinical trials, focused on populations at greatest risk from COVID-19 complications, including blood cancer patients scheduled to receive stem cell transplant therapy. In one of the ongoing Phase 2 trials, the mRNA control arm was discontinued due to poor immunogenicity with the remainder of the trial only including GEO-CM04S1 which surpassed the immunogenicity target, reinforcing the limitations of monovalent vaccines and the important value of a multi-antigen vaccine approach in such high-risk patient populations. 'There are more than 40 million immunocompromised individuals in the U.S. alone,' said Dodd. 'They are underserved by the current, FDA-approved vaccine options that deliver only an antibody response and require a better solution with both breadth and longevity of protection.' Public Vaccine Policy and Regulatory Changes Support Platform Diversification Recent guidance from the U.S. Food and Drug Administration (FDA) calls for diversified vaccine platforms and risk-based regulatory pathways. Additionally, the CDC's narrowed 2025–2026 booster recommendations - now focused on adults 65+ and immunocompromised individuals - closely mirror GeoVax's clinical strategy and target population. GEO-CM04S1 has been proposed under BARDA's Rapid Response Partnership Vehicle (RRPV) for surge manufacturing support and integration into long-term public health preparedness efforts. The proposal, 'Innovation in Clinical Manufacturing of MVA-Vectored COVID-19 Vaccines', was selected by the RRPV, pending funding availability. 'As public health moves toward more targeted, durable, and inclusive vaccination strategies, GEO-CM04S1 is positioned to deliver where first generation COVID-19 vaccines fall short,' Dodd added. In addition to targeting today's variants, GEO-CM04S1 is structurally designed to adapt to future mutations and serve as a platform for multi-pathogen preparedness. As part of GeoVax's broader MVA-based portfolio, the platform underpins vaccine candidates for Mpox, smallpox, and hemorrhagic fever viruses, offering scale and flexibility across infectious disease threats. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin(R), having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: Forward-Looking Statements This release contains forward-looking statements regarding GeoVax's business plans. The words 'believe,' 'look forward to,' 'may,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'should,' 'plan,' 'could,' 'target,' 'potential,' 'is likely,' 'will,' 'expect' and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax's immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax's viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax's immuno-oncology products and preventative vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: [email protected] 678-384-7220 Investor Relations Contact: [email protected] 212-698-8696 Media Contact: Jessica Starman [email protected]

M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates
M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates

Yahoo

time2 hours ago

  • Yahoo

M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates

-- Morgan Stanley has begun coverage of Genmab (CSE:GMAB) (NASDAQ:GMAB) with an Equal-Weight rating and a price objective of $24, reduced slightly from the previous $25 target. The Wall Street bank sees limited near-term upside as the most impactful catalysts are expected in 2026. 'Given that particular catalysts poised to most likely re-rate GMAB stock are anticipated to occur in 2026, we assume coverage at EW rating and look toward incremental updates on development timelines and commercial execution over the remainder of 2025,' analyst Judah C. Frommer said. Genmab is navigating a transition away from heavy reliance on Darzalex royalties and focusing more on its proprietary pipeline, particularly Epkinly, Rina-S, and acasunlimab. Following Johnson & Johnson (NYSE:JNJ)'s decision not to opt into the HexaBody-CD38 program, Frommer says attention will shift to maximizing internal pipeline value. For Epkinly, a supplemental BLA has been submitted in 2L+ follicular lymphoma based on the EPCORE-FL-1 study. While top-line data showed the study met one of its co-primary endpoints, progression-free survival data are still pending and expected later this year. More significant Phase III readouts for Epkinly in earlier-line DLBCL are scheduled for 2026. 'In the near-term however, focus remains on current commercial execution strategy in the 3L+ settings for DLBCL and FL as we await key data updates,' Frommer added. Meanwhile, Rina-S is progressing across multiple indications. At American Society of Clinical Oncology (ASCO), data in endometrial cancer showed response rates of 50% and 47% in two dose cohorts. The company plans to initiate a pivotal Phase III trial in 2L+ endometrial cancer in the second half of 2025 and a separate trial in platinum-sensitive ovarian cancer before year-end. Acasunlimab also remains a focus. Morgan Stanley expects updated Phase II data in 2L+ NSCLC later this year. The Phase III trial, which uses overall survival as the primary endpoint, is anticipated to read out in 2027. In sum, though Morgan Stanley views Genmab's management execution and pipeline-building strategy as sound, it sees 2026 as a more realistic timeframe for material stock re-rating. In the meantime, 'we look toward updates on development timelines and commercial execution over the remainder of 2025,' the bank said. Related articles takes neutral stance on Genmab ahead of portfolio, execution updates MS initiates coverage on AI Biotechs, flags key pipeline catalysts Chip stock targets raised at Mizuho following recent rally Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store